Walleye Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.7M Sell
427,300
-246,200
-37% -$11.7M 0.07% 259
2025
Q4
$34.3M Buy
673,500
+377,900
+128% +$19.3M 0.11% 122
2025
Q3
$16.4M Buy
295,600
+67,800
+30% +$3.97M 0.06% 323
2025
Q2
$15.7M Buy
227,800
+46,500
+26% +$3.16M 0.06% 326
2025
Q1
$12.6M Buy
181,300
+36,000
+25% +$2.97M 0.06% 345
2024
Q4
$12.5M Buy
145,300
+29,100
+25% +$3.15M 0.03% 507
2024
Q3
$13.8M Sell
116,200
-143,600
-55% -$19.2M 0.03% 522
2024
Q2
$37.1M Buy
259,800
+105,800
+69% +$14M 0.07% 179
2024
Q1
$19.8M Sell
154,000
-2,500
-2% -$298K 0.04% 425
2023
Q4
$16.2M Buy
156,500
+37,400
+31% +$3.7M 0.03% 428
2023
Q3
$10.8M Buy
119,100
+45,500
+62% +$4.01M 0.03% 523
2023
Q2
$5.96M Buy
73,600
+61,000
+484% +$4.98M 0.02% 634
2023
Q1
$1M Buy
+12,600
New +$893K 0.02% 1171
2022
Q4
Sell
-50,400
Closed -$2.51M 3496
2022
Q3
$2.51M Buy
+50,400
New +$2.7M 0.05% 446

Other funds holding NVO

Walleye Capital's NVO Position: Q1 2026 in Review

Walleye Capital increased its Novo Nordisk (NVO) stake by 16% in Q1 2026, buying an estimated $3.68M and bringing the position to 578,309 shares worth $21.3M. The position accounts for 0.09% of the portfolio, ranked #174.

Walleye Capital first reported a position in NVO in Q3 2023 and has held it in 11 quarters since. The position peaked at $30M in Q3 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Walleye Capital held 578,309 shares of Novo Nordisk worth $21.3M as of Q1 2026.
  • Walleye Capital bought 77,665 Novo Nordisk shares in Q1 2026, an estimated $3.68M.
  • Novo Nordisk made up 0.09% of Walleye Capital's portfolio in Q1 2026, its #174 holding.
  • Walleye Capital first reported a position in Novo Nordisk in Q3 2023 and has held it in 11 quarters since.
  • Walleye Capital's Novo Nordisk position peaked at $30M in Q3 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.